"The conference mission aligns closely with our corporate vision to revolutionize patient access by enabling rapid uptake of important diabetes technology for the people with insulin-requiring ...

Since the start of 2024, Wockhardt’s stock price has almost tripled to Rs 1,233.85 per share as on November 8.

The conference mission aligns closely with our corporate vision to revolutionize patient access by enabling rapid uptake of important diabetes technology for the people with insulin-requiring diabetes ...

Outside the United States, we also had a regulatory win in the European Union with the clearance of T:slim X2 for use with Lyumjev ultra-rapid-acting insulin. Ultra-rapid-acting insulin is a popular ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Harbor Capital Advisors Inc. lifted its stake in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 12.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC.

US Bancorp DE boosted its position in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 1.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission.